MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/jcsm.70243

Медицинская библиотека · Journal of cachexia, sarcopenia and muscle · 2026

Sarcopenia Predicts Outcome After Chemoimmunotherapy, Not Chemotherapy, in Advanced Lung Cancer: Single-Centre Retrospective Study.

Lee Hyojin, Kim Chang Gon, Han Sookyeong, Park Su Kyoung, Yoon Hong In, Kim Kyung Hwan, Shim Hyo Sup, Hong Min Hee, Yeo Ja Hyun, Kim Sangwoo, Hwang Sang Hyun, Kim Hye Ryun, Hong Namki

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Sarcopenia, characterized by progressive loss of skeletal muscle mass, is prevalent in patients with non-small cell lung cancer (NSCLC). While sarcopenia has been associated with poor prognosis in multiple types of cancer, its predictive role in the context of first-line treatment combining PD-(L)1 inhibitors with platinum-based chemotherapy (CITx) remains unclear in advanced NSCLC.

METHODS

In a single-centre retrospective cohort, patients with advanced NSCLC without actionable genomic alterations who received either CITx (n = 552) or platinum-doublet chemotherapy alone (CTx; n = 622) were analysed. Sarcopenia was defined on the Martin's computed tomography-derived skeletal muscle index definition. Progression-free survival (PFS) and overall survival (OS) were assessed. Interaction between sarcopenia and treatment modality was explored.

RESULTS

Sarcopenia was observed in 49.5% of patients. The presence of sarcopenia was associated with worse outcomes in overall patients (median OS: 9.4 vs. 11.4 months; HR 1.22, 95% CI 1.08-1.39). When stratified by treatment groups, sarcopenia was significantly associated with higher risk of progression (adjusted HR 1.23, 95% CI 1.01-1.49) and death (adjusted HR 1.42, 95% CI 1.16-1.74) in CITx-treated patients, whereas no such association was observed in the CTx group. The interaction between sarcopenia and treatment type was significant for both PFS (p = 0.041) and OS (p = 0.022).

CONCLUSIONS

Sarcopenia is a predictive biomarker for inferior outcomes in patients with advanced NSCLC treated with CITx, but not with CTx. Assessment of skeletal muscle mass can help identify patients at risk for suboptimal response to CITx. This study provides grounds for future exploration in interventions targeting sarcopenia and cachexia to enhance clinical outcomes in advanced cancer patients.

Для цитирования: Lee Hyojin, Kim Chang Gon, Han Sookyeong, Park Su Kyoung, Yoon Hong In, Kim Kyung Hwan, Shim Hyo Sup, Hong Min Hee, Yeo Ja Hyun, Kim Sangwoo, Hwang Sang Hyun, Kim Hye Ryun, Hong Namki. Sarcopenia Predicts Outcome After Chemoimmunotherapy, Not Chemotherapy, in Advanced Lung Cancer: Single-Centre Retrospective Study.. Journal of cachexia, sarcopenia and muscle. 2026. DOI: 10.1002/jcsm.70243.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.